Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib

BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent dru...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Endocrinol Metab
Glavni autori: Kroiss, Matthias, Megerle, Felix, Kurlbaum, Max, Zimmermann, Sebastian, Wendler, Julia, Jimenez, Camilo, Lapa, Constantin, Quinkler, Marcus, Scherf-Clavel, Oliver, Habra, Mouhammed Amir, Fassnacht, Martin
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204945/
https://ncbi.nlm.nih.gov/pubmed/31900481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgz318
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items